Photo of Justin Pritchard

Justin Pritchard

Assistant Professor


  • Biomedical Engineering

212 Wartik Building


Personal or Departmental Website

Research Areas:

Cell and Molecular Bioengineering, Cell Signaling and Cancer

Interest Areas:

Systems Biology, Synthetic Biology, Drug Resistance




  • BS, Biology, University of California, Los Angeles, 2006
  • Ph D, Computational and Systems Biology, Massachusetts Institute of Technology, 2012


Journal Articles

  • Laura Laencina, Violaine Dubois, Vincent LeMoigne, Albertus Viljoen, Laleh Majlessi and Justin Pritchard, 2018, "Identification of genes required for Mycobacterium abscessus growth in vivo with a prominent role of the ESX-4 locus", Proceedings of the National Academy of Science
  • Peter M Bruno, Yunpeng Liu, Ga Young Park, Yunko Murai, Catherine Koch, Timothy J Eisen, Justin Pritchard, Yves Pommier, Stephen J Lippard and Michael Hemann, 2017, "A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress", Nature Medicine
  • Jeremy Rock, Forest Hopkins, A Chavez, M Diallo, MR Chase, Elias Merrick, Justin Pritchard, Eric Rubin, George Church and Sarah Fortune, 2017, "Programmable transcriptional repression in mycobacteria using an orthogonal CRISPR interference platform.", Nature Microbiology, 2, (16274)
  • Boyang Zhao and Justin Pritchard, 2016, "Inherited Disease Genetics Improves the Identification of Cancer-Associated Genes", Plos Genetics, 12, (6), pp. e1006081
  • Justin Pritchard, Stephanie Lustgarten, Graeme Hodgson, Michele Baccarani, Jorge E Cortes, Michael W Deininger, Francois Guilhot, Andreas Hochhaus, Timothy P Hughes, Neil P Shah and others, 2015, "High-Resolution Analysis of the Relationship Between Ponatinib Dose and Molecular Response in CP-CML Patients in the PACE Trial", Clinical Lymphoma, Myeloma and Leukemia, 15, pp. S212
  • Theresa Baker, Sujata Nerle, Justin Pritchard, Boyang Zhao, Victor M Rivera, Andrew Garner and Francois Gonzalvez, 2015, "Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors", Oncotarget, 6, (32), pp. 32646
  • Corbin E Meacham, Lee N Lawton, Yadira M Soto-Feliciano, Justin Pritchard, Brian A Joughin, Tobias Ehrenberger, Nina Fenouille, Johannes Zuber, Richard T Williams, Richard A Young and others, 2015, "A genome-scale in vivo loss-of-function screen identifies Phf6 as a lineage-specific regulator of leukemia cell growth", Genes & development, 29, (5), pp. 483–488
  • Zhao Boyang, Justin Pritchard, Douglas Lauffenburger and Michael Hemann, 2014, "Minimization of intra-tumoral heterogeneity through rationally designed combination therapy.", Cancer Discovery, 4, (2), pp. 166-174
  • Joyce Wang, Justin Pritchard, Louis Kreitmann, Alexandre Montpetit and Marcel A Behr, 2014, "Disruption of Mycobacterium avium subsp. paratuberculosis-specific genes impairs in vivo fitness", BMC genomics, 15, (1), pp. 415
  • Justin Pritchard, Michael C Chao, Sören Abel, Brigid M Davis, Catherine Baranowski, Yanjia J Zhang, Eric J Rubin and Matthew K Waldor, 2014, "ARTIST: high-resolution genome-wide assessment of fitness using transposon-insertion sequencing", PLoS genetics, 10, (11), pp. e1004782
  • Justin Pritchard, Peter M Bruno, Kelsey Capron, Douglas Lauffenburger and Michael Hemann, 2013, "Defining genetic principles of combination chemotherapy", Proceedings of the National Academy of Sciences, 110, (2), pp. 9
  • Michael C Chao, Justin Pritchard, Yanjia J Zhang, Eric J Rubin, Jonathan Livny, Brigid M Davis and Matthew K Waldor, 2013, "High-resolution definition of the Vibrio cholerae essential gene set with hidden Markov model–based analyses of transposon-insertion sequencing data", Nucleic acids research, 41, (19), pp. 9033–9048
  • Justin Pritchard, Peter M Bruno, Michael T Hemann and Douglas A Lauffenburger, 2013, "Predicting cancer drug mechanisms of action using molecular network signatures", Molecular BioSystems, 9, (7), pp. 1604–1619
  • Justin Pritchard, 2012, "Understanding resistance to combination chemotherapy", Drug Resistance Updates, 15, (5), pp. 8
  • Justin Pritchard, 2011, "BCL-2 family genetic profiling reveals microenvironment-specific determinants of therapeutic response.", Cancer Research, 71, (17), pp. 8
  • Hai Jiang, Justin Pritchard, Richard T Williams, Douglas A Lauffenburger and Michael T Hemann, 2011, "A mammalian functional-genetic approach to characterizing cancer therapeutics", Nature chemical biology, 7, (2), pp. 92–100
  • Justin Pritchard, Benjamin D Cosgrove, Michael T Hemann, Linda G Griffith, Jack R Wands and Douglas A Lauffenburger, 2009, "Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death", Molecular cancer therapeutics, 8, (8), pp. 2183–2192
  • Benjamin D Cosgrove, Connie Cheng, Justin Pritchard, Donna B Stolz, Douglas A Lauffenburger and Linda G Griffith, 2008, "An inducible autocrine cascade regulates rat hepatocyte proliferation and apoptosis responses to tumor necrosis factor-$a$", Hepatology, 48, (1), pp. 276–288

Conference Proceedings

  • Michael Schmitt and Justin Pritchard, 2017, "Sub-clonal heterogeneity and risk of treatment failure in Philadelphia-positive leukemias", Cancer Research
  • Justin Pritchard, Michael W Schmitt, J Graeme Hodgson, Stephanie Lustgarten, Shijie Tang, Lawrence A Loeb, Jerald P Radich and Victor M Rivera, 2016, "Analysis of the Sub-Clonal Origins of Compound Mutations in Patients with Refractory Ph+ Malignancies Treated with Ponatinib", Blood, Am Soc Hematology
  • Victor M Rivera, Susan Branford, Franck E Nicolini, Justin Pritchard, Joseph M Gozgit, Wolfgang Kern, Dragana Milojkovic, Simone Claudiani, Martin C Muller, Srinivas K Tantravahi and others, 2015, "A Multi-Institutional Retrospective Analysis of Tyrosine Kinase Inhibitor (TKI) Clinical and Preclinical Efficacy According to BCR-ABL Mutation Status in CP-CML Patients", Am Soc Hematology
  • Michael W Schmitt, Justin Pritchard, Graeme Hodgson, Victor M Rivera, Bella I Aminov, Lan Beppu, Lawrence A Loeb and Jerald P Radich, 2015, "Emergence of sub-clonal drug resistance mutations during CML therapy", Blood
  • Justin Pritchard, S Lustgarten, JG Hodgson, M Baccarani, JE Cortes, MW Deininger, F Guilhot, TP Hughes, NP Shah, M Talpaz and others, 2015, "Analysis of the relationship between dose and BCR-ABL halving time in CP-CML patients treated with ponatinib or imatinib", 100, pp. 448–449
  • Michael C Heinrich, J Graeme Hodgson, Margaret von Mehren, George D Demetri, Jonathan A Fletcher, Jichao G Sun, Justin Pritchard, Sen Zhang, Victor M Rivera and Suzanne George, 2015, "Detection of KIT mutants in circulating tumor DNA (ctDNA) and their association with ponatinib anti-tumor activity in patients (pts) with advanced gastrointestinal stromal tumors (GIST).", American Society of Clinical Oncology
  • Victor M Rivera, Justin Pritchard, Francois Gonzalvez, Theresa Baker, Joseph M Gozgit and Graeme Hodgson, 2014, "Comparative TKI profiling analyses to explore potential mechanisms of ponatinib-associated arterial thrombotic events", Blood
  • Justin Pritchard, Stephanie Lustgarten, Graeme Hodgson, Michele Baccarani, Jorge E Cortes, Michael W Deininger, Francois Guilhot, Andreas Hochhaus, Timothy P Hughes, Neil P Shah and others, 2014, "High-resolution analysis of the relationship between dose and molecular response in CP-CML patients treated with ponatinib or imatinib", Am Soc Hematology

Research Projects

Honors and Awards

  • Teaching Fellow; LS120 Global Health Threats, Harvard University, 2012 - 2013
  • Poitras foundation fellowship in biomedical engineering, M.I.T., 2010
  • Presidential Fellow, M.I.T., 2006


Service to Penn State:

  • Participation in Development/Fundraising Activities, Attendee, Glaxo Smith Kline development in collaboration with the Huck Institute., 2018 - 2018
  • Participation in Development/Fundraising Activities, Moderator, Industry Xchange, College of Engineering, May 2018 - May 2018
  • Participation in Development/Fundraising Activities, Participant, Kolon visit to PSU, Kolon-COE, May 2018 - May 2018
  • Participation in Recruitment and Retention Activities, Evaluator, MCIBS Recruitment, Huck Institute, January 2018 - 2018
  • Other, Member, Proposal Writing, Relationship Building, Outreach to government and Military, January 2018
  • Participation in Development/Fundraising Activities, Attendee, Outstanding Engineering Alumni, 2018 - 2018

Service to External Organizations:




The Department of Biomedical Engineering administers the undergraduate major in biomedical engineering, and is a part of the university-wide Intercollege Graduate Degree Program, offering both M.S. and Ph.D. degrees in Bioengineering. Our work combines traditional engineering principles with medicine and technology for the betterment of human health and society. 

Department of Biomedical Engineering

205 Hallowell Building

The Pennsylvania State University

University Park, PA 16802-4400

Phone: 814-863-6614